| Name | Title | Contact Details |
|---|
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.
Rain Oncology is a clinical stage company researching, developing and translating innovative targeted therapies for patients with cancer.
Pulmocide is a biotechnology company focused on the development of inhaled medicines for the treatment of viral and fungal infections of the respiratory tract.
Reimagining Healthcare. UrgentPoint is committed to combining health and wellness and meeting the patient where they are, every time. With a multispecialty medical group, a medical management company, and an electronic health records technology company...
Institute for OneWorld Health is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.